JPWO2020130269A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020130269A5 JPWO2020130269A5 JP2021536744A JP2021536744A JPWO2020130269A5 JP WO2020130269 A5 JPWO2020130269 A5 JP WO2020130269A5 JP 2021536744 A JP2021536744 A JP 2021536744A JP 2021536744 A JP2021536744 A JP 2021536744A JP WO2020130269 A5 JPWO2020130269 A5 JP WO2020130269A5
- Authority
- JP
- Japan
- Prior art keywords
- dna aptamer
- cancer
- composition
- seq
- base sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008102 DNA aptamers Proteins 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 150000001982 diacylglycerols Chemical class 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 1
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- DASWEROEPLKSEI-UIJRFTGLSA-N monomethyl auristatin e Chemical group CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 claims 1
- MFRNYXJJRJQHNW-NARUGQRUSA-N monomethyl auristatin f Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)C([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-NARUGQRUSA-N 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical group C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 1
- 229950004354 phosphorylcholine Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000009958 sewing Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180167948 | 2018-12-21 | ||
| KR10-2018-0167948 | 2018-12-21 | ||
| PCT/KR2019/009956 WO2020130269A1 (ko) | 2018-12-21 | 2019-08-08 | 신규한 dna 앱타머 및 이의 용도 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022516054A JP2022516054A (ja) | 2022-02-24 |
| JPWO2020130269A5 true JPWO2020130269A5 (https=) | 2022-07-14 |
| JP2022516054A5 JP2022516054A5 (https=) | 2022-07-14 |
| JP7391971B2 JP7391971B2 (ja) | 2023-12-05 |
Family
ID=71100532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536744A Active JP7391971B2 (ja) | 2018-12-21 | 2019-08-08 | 新規のｄｎａアプタマー及びこれの用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12398395B2 (https=) |
| EP (1) | EP3901287A4 (https=) |
| JP (1) | JP7391971B2 (https=) |
| KR (1) | KR102324242B1 (https=) |
| CN (1) | CN113646442B (https=) |
| WO (2) | WO2020130225A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020130225A1 (ko) * | 2018-12-21 | 2020-06-25 | 국립암센터 | 췌장암 특이적으로 결합하는 dna 앱타머 및 이의 용도 |
| KR102506295B1 (ko) | 2020-08-28 | 2023-03-08 | 국립암센터 | 디그옥시제닌에 대한 인간화 항체 및 이의 용도 |
| KR102506288B1 (ko) * | 2020-09-07 | 2023-03-06 | 국립암센터 | 디그옥시제닌에 대한 항체를 포함하는 복합체, 및 이들의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US8563711B2 (en) * | 2009-06-01 | 2013-10-22 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid aptamer capable of binding specifically to pancreatic cancer cells or tissues and use thereof |
| KR101250557B1 (ko) * | 2011-05-18 | 2013-04-03 | 국립암센터 | Ｐａｕｆ 특이적 앱타머 및 이를 포함하는 췌장암 치료용 조성물 |
| KR101699105B1 (ko) * | 2012-04-02 | 2017-01-23 | 성균관대학교산학협력단 | Ａｌｐｐｌ２ 단백질을 이용한 췌장암 진단 방법 |
| KR101568400B1 (ko) * | 2012-08-09 | 2015-11-12 | 연세대학교 산학협력단 | 암 줄기세포에 특이적으로 결합하는 핵산 앱타머 및 이의 용도 |
| KR101458947B1 (ko) * | 2013-03-05 | 2014-11-12 | 국립암센터 | 인터루킨-８ 앱타머 및 이의 용도 |
| AU2016346269A1 (en) * | 2015-10-30 | 2018-05-24 | Tagcyx Biotechnologies | DNA aptamer binding to cancer cell |
| WO2020130225A1 (ko) * | 2018-12-21 | 2020-06-25 | 국립암센터 | 췌장암 특이적으로 결합하는 dna 앱타머 및 이의 용도 |
| KR102506295B1 (ko) * | 2020-08-28 | 2023-03-08 | 국립암센터 | 디그옥시제닌에 대한 인간화 항체 및 이의 용도 |
| KR102506288B1 (ko) * | 2020-09-07 | 2023-03-06 | 국립암센터 | 디그옥시제닌에 대한 항체를 포함하는 복합체, 및 이들의 용도 |
-
2019
- 2019-02-01 WO PCT/KR2019/001416 patent/WO2020130225A1/ko not_active Ceased
- 2019-08-08 CN CN201980092801.6A patent/CN113646442B/zh active Active
- 2019-08-08 EP EP19900348.4A patent/EP3901287A4/en active Pending
- 2019-08-08 JP JP2021536744A patent/JP7391971B2/ja active Active
- 2019-08-08 WO PCT/KR2019/009956 patent/WO2020130269A1/ko not_active Ceased
- 2019-08-08 US US17/416,858 patent/US12398395B2/en active Active
- 2019-08-08 KR KR1020190096665A patent/KR102324242B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Satchi-Fainaro et al. | Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 | |
| Vogus et al. | A review on engineering polymer drug conjugates to improve combination chemotherapy | |
| ES2983582T3 (es) | Composiciones bioortogonales | |
| Gillies et al. | Biological evaluation of polyester dendrimer: poly (ethylene oxide)“bow-tie” hybrids with tunable molecular weight and architecture | |
| TWI246922B (en) | Pharmaceutical compositions of water soluble paclitaxel derivatives for the treatment of a tumor | |
| Petersen et al. | Synthesis, characterization, and biocompatibility of polyethylenimine-g raft-poly (ethylene glycol) block copolymers | |
| Jiang et al. | Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting | |
| Neu et al. | Bioreversibly crosslinked polyplexes of PEI and high molecular weight PEG show extended circulation times in vivo | |
| Noh et al. | Pegylated poly-l-arginine derivatives of chitosan for effective delivery of siRNA | |
| Noga et al. | The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes | |
| JP5544357B2 (ja) | 水酸基を有する生理活性物質の高分子結合体 | |
| TW200812572A (en) | Polymer conjugate of taxane | |
| Cheng et al. | Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy | |
| Nejabat et al. | Graphene as multifunctional delivery platform in cancer therapy | |
| Liu et al. | An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy | |
| Wang et al. | A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma | |
| CA2463974A1 (en) | Dendrimers for use in targeted delivery | |
| Sk et al. | Enhancing the efficacy of Ara-C through conjugation with PAMAM dendrimer and linear PEG: a comparative study | |
| JPWO2012067138A1 (ja) | 新規なシチジン系代謝拮抗剤の高分子誘導体 | |
| Yadav et al. | Commercial aspects and market potential of novel delivery systems for bioactives and biological agents | |
| Zhu et al. | Efficient poly (N-3-hydroxypropyl) aspartamide-based carriers via ATRP for gene delivery | |
| CN114158253A (zh) | 强效细胞毒性化合物的pHLIP®靶向递送 | |
| JP2022516054A5 (https=) | ||
| Wu et al. | Anti-tumor activity of folate targeted biodegradable polymer–paclitaxel conjugate micelles on EMT-6 breast cancer model | |
| Namgung et al. | Synergistic effect of low cytotoxic linear polyethylenimine and multiarm polyethylene glycol: study of physicochemical properties and in vitro gene transfection |